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Artesunate-mefloquine combination therapy in acute
Plasmodium falciparum malaria in young children: a field study
regarding neurological and neuropsychiatric safety
Abstract
BACKGROUND: Mefloquine-artesunate combination therapy for uncomplicated falciparum malaria is
one of the treatments used in African children. Data concerning neurological safety in adults and
children treated with mefloquine and artesunate combination therapy is well documented in Asia. Safety
data for neurological and neuropsychiatric side effects of mefloquine and artesunate combination
therapy in African children are scarce, although WHO recommends this therapy in Africa.
METHODS: A phase IV, open label, single arm study was conducted among African children between
10 and 20 kg with acute uncomplicated falciparum malaria. They were treated over three consecutive
days with a paediatric fixed-dose combination of artesunate (50 mg/d) and mefloquine (125 mg/d).
Parasitological, clinical and neurological examinations and standardized questions about
neuropsychiatric symptoms were carried out on days 0, 4, 7, 28 and 63. The primary objective was to
assess the neurological and neuropsychiatric safety of artesunate-mefloquine combination therapy in
young children.
RESULTS: From December 2007 to March 2009, 220 children with uncomplicated Plasmodium
falciparum malaria were treated with artesunate and mefloquine. 213 children were analysed according
to study protocol. 50 neurological and neuropsychiatric adverse events occurred in 28 patients. Eleven
drug-related neurological and neuropsychiatric adverse events occurred in eight patients. Sleeping
disorders were present in 2.3%, neurological disorders in 1.4%, neuropsychiatric disorders in 1% and
eating disorders in 0.5% of the patients. Adverse events were of mild to moderate intensity and resolved
spontaneously.
CONCLUSION: African children showed a low percentage of self-limited neurological and
neuropsychiatric adverse events, confirming studies on neurological safety in Asian children treated
with artesunate and mefloquine. Sleeping disorders were most frequently observed.
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Abstract
Background: Mefloquine-artesunate combination therapy for uncomplicated falciparum malaria is one of the
treatments used in African children. Data concerning neurological safety in adults and children treated with
mefloquine and artesunate combination therapy is well documented in Asia. Safety data for neurological and
neuropsychiatric side effects of mefloquine and artesunate combination therapy in African children are scarce,
although WHO recommends this therapy in Africa.
Methods: A phase IV, open label, single arm study was conducted among African children between 10 and 20 kg
with acute uncomplicated falciparum malaria. They were treated over three consecutive days with a paediatric
fixed-dose combination of artesunate (50 mg/d) and mefloquine (125 mg/d). Parasitological, clinical and
neurological examinations and standardized questions about neuropsychiatric symptoms were carried out on days
0, 4, 7, 28 and 63. The primary objective was to assess the neurological and neuropsychiatric safety of artesunate-
mefloquine combination therapy in young children.
Results: From December 2007 to March 2009, 220 children with uncomplicated Plasmodium falciparum malaria
were treated with artesunate and mefloquine. 213 children were analysed according to study protocol. 50
neurological and neuropsychiatric adverse events occurred in 28 patients. Eleven drug-related neurological and
neuropsychiatric adverse events occurred in eight patients. Sleeping disorders were present in 2.3%, neurological
disorders in 1.4%, neuropsychiatric disorders in 1% and eating disorders in 0.5% of the patients. Adverse events
were of mild to moderate intensity and resolved spontaneously.
Conclusion: African children showed a low percentage of self-limited neurological and neuropsychiatric adverse
events, confirming studies on neurological safety in Asian children treated with artesunate and mefloquine.
Sleeping disorders were most frequently observed.
Background
Malaria is an important cause of infant morbidity and
mortality in African children, especially in young chil-
dren who lack immunity. According to the World
Health Organization (WHO), 36% of African children of
<5 years receive anti-malarial treatment. The infant
mortality rate (< 5 y) in Africa is 145/1000 live births/
year, of which 15.6% are caused by malaria (= 22,6/1000
live births/y). In some African countries infant mortality
caused by malaria is as high as 29.7% [1].
Effective treatment is very important and has become
more difficult due to emerging drug resistance. Since
2006 the WHO recommends artesunate plus amodia-
quine, artesunate plus lumefantrine and artesunate plus
sulphadoxine/pyrimethamine as first-line treatment for
uncomplicated Plasmodium falciparum malaria in
Africa. Artemisinin-based combination therapy has pro-
ven to be highly effective and safe. A rapid clearance of
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parasitaemia and a rapid solution of clinical symptoms
have been shown in several clinical trials and in every
day use. In Asia artesunate plus mefloquine is recom-
mended by the World Health Organization for children
and adults since 2006. In 2010, WHO released new
recommendations, which include artesunate plus meflo-
quine therapy for uncomplicated P. falciparum malaria
in Africa. This combination is well tolerated in every
day use and shows excellent efficacy combined with a
good safety profile in several clinical trials [1-4].
In adults, mefloquine is known to show, especially in
long-term prophylaxis, a variety of rare neurological/
neuropsychiatric adverse effects, for example headache,
vertigo, insomnia, depression, anxiety, sensory and
motor neuropathy, tinnitus, reversible hypoacusis and
myopathy. The elimination half-life of mefloquine varies
from 14 to 41 days and sub-therapeutic concentrations
persist in the body for several months [5].
No data regarding specific neurological/neuropsychia-
tric adverse effects of mefloquine combination therapy
with artesunate for African children has been published,
whereas data for Asian children are available [2,3]. The
presence and quality of neurological/neuropsychiatric
adverse effects may not have been reported because they
would not have been recognized due to the young age of
the children. It is possible that parents do not associate
the neuropsychiatric or neurological side effects with
the treatment of malaria, especially with respect to the
delay between the intake and the occurrence (mean
half-life of mefloquine is 21d). A study in Asian children
regarding neurological safety after use of mefloquine
and mefloquine-artesunate combination therapy in
uncomplicated falciparum malaria showed no significant
decrease in neurological performance in comparison to
a control group [1]. This study aimed at quantifying effi-
cacy and neurological and neuropsychiatric safety in a
three-day artesunate-mefloquine combination therapy of
acute falciparum malaria during everyday use in infants
and young children in Africa.
Methods
The clinical trial protocol was approved by the national
Ethic Committee of Yaoundé, Cameroon, and by the
Ethics Committee of the Technical University of Dres-
den, Medical Faculty, Germany. This study is registered
with ClinicalTrials.gov as NCT00978172.
Study population
Young children between 10 and 20 kg of weight attend-
ing the Clinic of Centre Mère et Enfant de la Fondation
Chantal Biya in Yaoundé, Cameroon, were considered
for enrolment if they presented with acute uncompli-
cated P. falciparum malaria (according to WHO cri-
teria). Inclusion criteria: count of asexual forms of
P. falciparum between 2,000 (amended to 1,000 μl of
blood) and 250,000 parasites, fever or history of fever,
written informed consent of the guardian, and the ability
of the child to take oral medication.
Exclusion criteria: children were excluded if they suf-
fered from severe malaria (according to WHO criteria),
or had a history or evidence of clinically significant neu-
rological, psychiatric, cardiovascular, pulmonary, meta-
bolic, gastrointestinal, oncologic or endocrine disease. In
addition, children were excluded if they were treated
with anti-malarial drugs within 7 days prior to diagnosis
or if they had participated in any investigational drug
trial within 30 days prior to enrolment. Further exclu-
sion criteria were vomiting three or more times within
24 h of enrolment, more than three copious liquid
stools within 24 h, parenteral treatment, allergy to arte-
sunate or mefloquine, splenectomy, HIV infection, or
renal impairment.
Protocol
A full medical history and clinical examination was car-
ried out after obtaining consent from the children’s
guardians. The neurological and neuropsychiatric assess-
ment was performed before administration of the study
drug and presented the baseline value.
According to the study protocol, examination visits
took place on baseline, and days 4, 7 (±1), 28 (±2) and
63 (±4). Malaria blood smears were checked on each
visit and PCR blood samples were taken at each visit.
Haematological exams (haemoglobin, haematocrit, RBC,
WBC) were carried out on baseline and days 4, 7, 28
and 63. A complete physical examination was carried
out on baseline and day 63. Vital signs and symptoms of
malaria were recorded during every visit. Adverse events
could be reported any time, at the latest on the next
visit.
Adverse events were defined and classified as “mild”,
“moderate” and “severe” according to ICH Harmonised
Tripartite Guideline for Good Clinical Practice E6 (R1)
[6]. All adverse events were recorded. For evaluation
they were divided into “drug-related” (“certain”, “prob-
ably”, “possibly” and “unlikely”) and “not drug-related”.
A written statement by the investigator was required to
justify why the neurological and neuropsychiatric
adverse event was not drug-related.
Anti-malarial drug treatment
Anti-malarial treatment was given over three consecu-
tive days with a daily oral dose of Artequin® Paediatric
(Stick pack) containing 50 mg of artesunate and 125 mg
of mefloquine in a fixed combination. The first dose was
given to the child by the investigator in the health cen-
tre, the second and third doses by the guardian of the
child at home. If vomiting occurred within the first
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30 minutes after intake, a full replacement dose (one
stick pack) was given. Replacement was possible only
once. The guardians had to return empty stick packs on
day 4 to the investigator in order to verify compliance
with the treatment schedule. The Study medication was
provided by Mepha Ltd, Aesch, Switzerland.
The neurological and neuropsychiatric examination
The neurological and neuropsychiatric examination took
place on the baseline visit and on days 7, 28 and 63.
Performing the examination took approximately 30 min-
utes. Children were questioned and examined by the
same investigator during all visits. Three experienced
paediatricians of the Centre Mère et Enfant de la Foun-
dation Chantal Biya were trained in the use of the
questionnaire and in the standardized neurological
assessment with a video recording of the examination
and by examining volunteer patients according to the
protocol. This training involved demonstrating the tests
and then getting the investigator to perform and score
the examination by consensus. During the study course,
the training was repeated after 7 months.
Phrasing and questions were tested in about 15
patients and guardians in Yaounde, Cameroon prior to
the beginning of the study to ensure, that the questions
were well understood by the guardians to identify accu-
rately the neuropsychological symptoms.
The neurological and neuropsychiatric examination
included 23 questions to the guardian concerning his/
her observations, questions to the child (older than
3.5 y as a rule), the investigators observations and
twelve clinical assessments. The questionnaire was
available in French and English, containing twenty-
three prephrased questions covering dizziness, vertigo,
headache, convulsions, paraesthesia (only >3.5 y), dys-
aesthesia (only >3.5 y), insomnia, nightmares (only >5
y), hyperactivity, anxiety, panic attacks, sadness, mood
changes, confusion, aggressive behaviour, tension,
visual hallucinations, acoustic hallucinations (only >3.5
y), hearing loss, dysarthria, word-finding disturbance
(only >3.5 y), eating behaviour and swallowing distur-
bance. Questions were addressed to the guardian with
specific questions to the child him/herself. To avoid
misunderstanding or misinterpretation, all investigators
used the same terms to ask those questions.
The neurological examination covered twelve items:
tremor, dystonia and ataxia, hyperreflexia, hyporeflexia,
clonus, dysdiadochokinesis, disturbed vision, nystagmus,
double vision, acoustic acuity, forgetfulness, and word-
finding disturbance. For this exam investigators were
equipped with an examination set containing a descrip-
tion of the examination process, a reflex hammer, a lamp
and a Lang Stereo Vision test (item disturbed vision), five
coloured building blocks (item forgetfulness), a toy car
(item word-finding disturbance), and a Denver Develop-
mental test.
Tremor, dystonia and ataxia, hyperreflexia, hypore-
flexia, clonus, dysdiadochokinesis, nystagmus, double
vision and acoustic acuity were tested doing a standard
paediatric neurological examination based on Touwen
[7]. Word-finding disturbance was tested by showing
the child a toy car, a bird (or telephone), a key, a pen, a
chair and asking to name the object. A score of “NOT
present” for word-finding disturbance was given if the
child could name all objects promptly.
Some exams/questions were age restricted to certain
age limits or modified according to the age of the child.
Item forgetfulness was tested in children younger than
3.5 years by presenting the child 3 coloured building
blocks in a given order and letting the child repeat the
placement after mixing the building blocks. Forgetful-
ness in children older than 3.5 years was tested by enu-
merating number groups. To begin the test, the child
had to repeat two groups of two digits, then two groups
of three digits, then two groups of four digits, then two
groups of five digits.
During the baseline visit, it was recorded whether a 2-
digit, 3-digit, 4-digit or 5-digit group could be repeated,
and a score of one point per correct repeat was given.
During follow-up visits, the forgetfulness was recorded
as “present” if there was a decrease in the digit group
that could be repeated. For example, if a child was able
at baseline to repeat a 4-digit group but could not
repeat a 3-digit group on day 28, this was marked as
presence of forgetfulness. This procedure was chosen in
accordance with tasks from cognitive tests such as Ham-
burg Wechsler Intelligence Test for Children [8] or
Kaufman-Assessment Battery for Children [9].
Children could refuse to participate. If the exam could
not be performed investigators scored this with “not
done”. Otherwise questions were scored with “yes (dis-
order present) “ or “no (disorder not present) “ at base-
line. In the follow-up visits questions were scored with
“no (disorder not present) “ or “yes (disorder present,
still the same)” or “yes (disorder present, improved)” or
“yes (disorder present, worsened or new)” in which case
an adverse event was reported. The option “not done”
was chosen if the child was not cooperating. All children
were followed up for fever and parasite clearance irre-
spective of their participation in neurological and neu-
ropsychiatric examinations.
Only the appearance of new symptoms - occurring
after baseline - was evaluated as an adverse event. If a
child was already hyperactive before taking the study
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medication, this was not considered as an adverse event
at the next study visit, if it was still present. But if
hyperactivity appeared newly afterwards during the
study course or worsened during two visits, it was
reported as an adverse event.
The clinical neurological and neuropsychiatric exami-
nation is based on standard paediatric neurological
examination (based on Touwen [7]); the questionnaire
was adapted to symptoms recorded in adults during
mefloquine treatment or prophylaxis. With respect to
the absence of a standardized test for paediatric neuro-
logical and neuropsychiatric evaluation in this age group
in a resource-poor setting, the Division of Child Neurol-
ogy of the University Children’s Hospital of Basel, Swit-
zerland, developed the examination setting used in this
study.
Laboratory procedure
Laboratory procedures have been described elsewhere
[10].
Concomitant medication
Concomitant medication was recorded; children taking
other malaria treatments due to a new malaria episode
completed all visits up to day 63, but evaluation for neu-
rological and neuropsychiatric events was only validated
until the day beginning the concomitant malaria
medication.
Statistical methods for evaluating neurological and
neuropsychiatric safety
Only children who took at least one dose of study medi-
cation and who had the neuropsychiatric and neurologi-
cal exam at least at baseline and day 7 or had a drug-
related neurological or neuropsychiatric adverse event
were included in the statistical evaluation of neuropsy-
chiatric and neurological safety. The proportion of
adverse events was calculated as well as the confidence
interval.
Results
Study participants
From December 2007 to March 2009, 220 children with
uncomplicated P. falciparum malaria were included in
the study, of which 184 children (83.6%) concluded the
study according to protocol. 3,800 children had been
screened (including blood smear), 220 met the inclusion
criteria; 94% were not included because of negative
blood smear or parasite count less than 2,000 (amended
to 1,000 μl of blood) or more than 250,000. Data from
213 patients were analysed for neuropsychiatric and
neurological safety. Two patients were classified as early
treatment failure; five patients had no follow-up visits
and were not evaluable for neuropsychiatric and neuro-
logical safety.
The youngest child included was seven months old;
the oldest seven years and nine months. The mean age
was three years and four months. (27 children were
younger than 1.5 years, 104 children were between 1.5
and 3.5 years, 51 children were 3.5 to 5 years old and
31 children were older than 5 years). Gender distribu-
tion was equal: 104 boys (48.8%) and 109 girls (51.2%)
participated in the study.
Neurological and neuropsychiatric outcome (safety)
Fifty neuropsychiatric and neurological adverse events
occurred in 28 children (13%). Eleven neuropsychiatric
and neurological adverse events in eight children (out of
213; 5.16%) were related to the study medication. (Table
1 and Figure 1). The frequency of the occurrence of at
least one neuropsychiatric and neurological adverse
event related to the study medication was 3.77%, (95%
CI 1.6-7.3%). The age distribution of drug-related neu-
ropsychiatric and neurological adverse events did not
reveal any differences (age group <1.5 years 3.7%, 1.5-
3.5 years: <3.8%, 3.5-5 years: 3.9%, >5 years: 3.7%).
Results of the registration of neurological and neurop-
sychiatric disorders at baseline are shown in Table 2. At
baseline, hyporeflexia or dystonia (hypotonia) were pre-
sent in 5.4% of the children. At baseline, altered eating
behaviour was present in 72% of the children. During
the study reported drug-related neurological and neu-
ropsychiatric adverse events were of mild (45.5%) or
moderate (54.5%) intensity. Onset of the drug-related
adverse events occurred during the first five days after
baseline in 45% of the children, an additional 36%
occurred between days 5 and 15. The latest adverse
event was recorded on day 31. Resolution of the adverse
events occurred 10 days after onset in 81% of the
adverse events. The resolution of one adverse event
(moderate hyperactivity) was not clear, because of insuf-
ficient follow-up; all other adverse events were resolved
spontaneously (Figure 2).
The most common drug-related adverse events were
sleeping disorders (2.3%), insomnia (4/213 children,
1.9%) and nightmares (1/31 children 3.2%). Neurological
disorders were present in three children (1.4%): vertigo
(0.5%), dizziness (0.5%), headache (0.5%). Neuropsychia-
tric disorders (1%) were present in one child who had
two adverse events: hyperactivity (0.5%) and aggressive
behaviour (0.5%). Abnormal eating behaviour (0.5%) was
present in one other child.
One serious neurological and neuropsychiatric adverse
event, which was classified as not drug-related, occurred.
The child was suffering from convulsions during the night
after baseline and was hospitalized. The convulsions were
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attributed to the underlying disease (malaria), and resolu-
tion under different malaria medication was achieved
without complications.
Non-neurological and neuropsychiatric outcome (safety)
There were five serious adverse events in four children
during 63 days of follow-up. One child was hospitalized
twice because of anaemia, two children were hospita-
lized because of severe malaria, and one child was hos-
pitalized because of asthenia. All were classified to be
not drug-related. A total of 169 non-neurological and
neuropsychiatric adverse events in 112 patients have
been reported. Eleven of the 169 other adverse events
were classified as related to the study drug. The most
frequently related adverse event was anaemia (6 children
2.8%), followed by diarrhoea (2 children 0.9%), vomiting
(2 children 0.9%) and sleep disorder (1 patient 0.5%). All
of the related adverse events were mild or moderate in
intensity. Precise description and discussion is published
elsewhere [10].
Parasitological outcome (efficacy)
PCR corrected ACPR (Adequate clinical and parasitolo-
gical response) rates were 96.6% (95% CI: 93.0 to 98.4%)
for day 28 and for day 63. Four patients were classified
as late clinical failures and three patients as early treat-
ment failures. There were 22 new infections up to day
63 which could be confirmed as new malaria episodes
by PCR. Median time for the children who were suffer-
ing from a new infection was 56 days. More detailed
information about the parasitological outcome is pub-
lished elsewhere [10].
Concomitant medication
75.3% of all participating children were treated with
analgesics as concomitant medication during the study
course. 51.2% of the children took anti-anaemic medica-
tion. 18.6% of the children were treated with anti-
inflammatory and anti-rheumatic medication. 8.4% of
the children were treated with anti-helmetic medication.
Cough and cold preparations were given to 7.4% of all
children included in the study. 7.7% of the included
children were treated with other medications. Duration
of concomitant medications varied.
Discussion
Detailed neurological and neuropsychiatric safety evalua-
tion among African children aged 7 months to 7 years
was performed after artesunate-mefloquine treatment of
acute P. falciparum malaria. Patients from a district hos-
pital represented the diversity of the population though
the study was a single centre study. The large number
(94%) of children screened but not included represents
Table 1 Occurrence of drug-related neuropsychiatric and
neurological adverse events
Neuropsychological
or neurological
symptom
Number of patients suffering
from at least one event/
number of analyzed patients*
95-%
confidence
interval
Dizziness 1/213 0.0 - 2.59%
Headache 1/209 0.0 - 2.64%
Vertigo 1/211 0.0 - 2.61%
Convulsions 0/212 0.0 - 1.72%
Paraesthesia 0/76 0.0 - 4.74%
Dysaethesia 0/76 0.0 - 4.74%
Sleeplessness
(insomnia)
4/213 0.5 - 4.74%
Nightmares 1/30 0.1 - 17.2%
Hyperactivity 1/213 0.0 - 2.59%
Anxiety 0/213 0.0 - 1.72%
Panic Attack 0/213 0.0 - 1.72%
Unexplained sadness 0/213 0.0 - 1.72%
Mood changes 0/213 0.0 - 1.72%
Confusion 0/212 0.0 - 1.72%
Aggressive behavior 1/213 0.0 - 2.59%
Tension 0/213 0.0 - 1.72%
Visual hallucinations 0/80 0.0 - 4.51%
Acoustic
hallucinations
0/76 0.0 - 4.74%
Hearing loss 0/211 0.0 - 1.73%
Dysarthria 0/209 0.0 - 1.75%
Word finding
disturbance (1)
0/204 0.0 - 1.79%
Eating behavior 1/213 0.0 - 2.59%
Swallowing
disturbance
0/213 0.0 - 1.72%
Tremor 0/211 0.0 - 1.73%
Dystonia, ataxia 0/212 0.0 - 1.72%
Hypereflexia 0/213 0.0 - 1.72%
Hyporeflexia 0/213 0.0 - 1.72%
Clonus 0/213 0.0 - 1.72%
Dysdiadochokinesis 0/164 0.0 - 2.22%
Disturbed vision 0/151 0.0 - 2.41%
Nystagmus 0/199 0.0 - 1.84%
Double vision 0/71 0.0 - 5.06%
Acoustic acuity 0/122 0.0 - 2.98%
Forgetfullness 0/93 0.0 - 3.89%
Word finding
disturbance (2)
0/72 0.0 - 4.99%
Nightmares were only assessed in children 5 years in age or older.
Paraesthesia, dysaethesia, visual and acoustic hallucinations, double vision and
word finding disturbance (2) were only assessed in children 3.5 years in age
or older.
Acoustic acuity was only assessed in children 1.5 years in age and or older.
* N = Number of patients who had the examination at Day 7 or for whom the
related NNAE was reported at any time.
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the reality in African cities where the clinical criteria of
malaria often do not correspond with parasitaemia
(parasite count in the blood smear). This leads to a
large number of un-needed applications of anti-malarial
therapy and aids the development of resistance against
anti-malarial therapy.
One of the advantages of this study was to evaluate a
large study population (213 children) under every day
conditions. Study results show a very good efficacy [10],
and neurological and neuropsychiatric safety for the
paediatric fixed-dose combination artesunate-
mefloquine.
Clinical neurological performance and neuropsychia-
tric status did not deteriorate (after treatment) in 96.2%
of the children during the study. 3.8% of the children
had a transient drug-related mild to moderate neurolo-
gical or neuropsychiatric impairment, which resolved
spontaneously.
Sleeping disorders were the most frequently observed
neurological and neuropsychiatric adverse events. This
confirms results of other studies conducted for safety in
mefloquine or combined mefloquine-artesunate therapy
in adults and children as malaria chemoprophylaxis or
for treatment of uncomplicated falciparum malaria,
where sleeping disturbance was a common adverse
event [11,12]. An interesting point is that the adverse
events (abnormal eating behaviour, headache, dizziness,
sleeplessness and nightmares), which were reported by
parents during the first five days of the study, were all
disorders that could be attributed to the acute malaria
episode.
Dizziness was the most common adverse event in
other studies [13]. Dizziness often occurred at baseline,
but only in one child (0.5%) during the post-treatment
observation period. Aggressive behaviour or hyperactiv-
ity as adverse events were previously not reported
among children after mefloquine-artesunate therapy in
uncomplicated acute falciparum malaria. Both neuropsy-
chiatric adverse events occurred in the same child (0.5%
for each adverse event) and were most likely attributed
to mefloquine. Case reports in children and studies in
adults treated with mefloquine monotherapy or meflo-
quine combination therapy for prophylaxis or acute
therapy [12,14], describe rare cases of mania, psychotic
episodes, and anxiety attacks. Such events were not
observed in the present study.
To date, only one study [2] has focused on CNS
effects in young children with artesunate-mefloquine
combination therapy. This study was conducted from
1994 to 1997 in ninety-eight Asian children and used a
specified neurological assessment for children (Shoklo
Neurological Test and Shoklo Developmental Test [15]).
Repeated assessments in children aged three months to
five years were conducted until day 28 after first intake
of mefloquine-artesunate therapy. 45 children received
an artesunate mono-therapy with a total dose of 12 mg/
kg over 6 days, 46 children received an artesunate (12
mg/kg total dose) + mefloquine (25 mg/kg total dose)
combination therapy over 8 days. 36 children were
healthy control subjects.
The neurological assessment included evaluation of
tonus, coordination, the status of consciousness, the
emotional status and the social orientation [15]. In
accordance with the presented data, this study showed
no deterioration or deficits in coordination and tonus
due to mefloquine-artesunate therapy, the other para-
meters showed no deterioration either, but were not
directly comparable to items in our study.
A large sample (213 children) of a concise age group of
children (7 month to 7 years) weighing 10-20 kilograms
was investigated. Neuropsychiatric and neurological disor-
ders were accurately recorded by a specific standardized
questionnaire containing 23 questions in the present
study. Tone and coordination disorders were evaluated in
the same way as the other neurological disorders by the
investigator in the clinical neurological exam as “present”
or “not present” with only two items, which had to be
quantified. Questions and neurological exams were age-
adapted regarding the investigated symptom. For most
questions and exams the investigation was different for
children younger and older than 3.5 years. Questions and
examinations were adapted to the applicability of the
Figure 1 Number and intensity of drug related N+N adverse events.
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examination to the developmental status of the age of the
children: for example nightmares were only applicable in
children older than 5 years, because it was not possible to
identify a nightmare in younger children according to
their developmental status.
Because of the long half-life of mefloquine with mea-
surable blood levels of mefloquine up to 41 days [16],
neurological and neuropsychiatric assessments were
done until day 63. Thus, late onset neurological and
neuropsychiatric adverse events were recorded in con-
trast to the study by Ambler et al [2]. Hyperactivity, as
the only neuropsychiatric adverse event (0.5%), was
detected after day 28.
Standardized tests for detecting deficits in neuromoto-
ric skills and abnormal neuropsychiatric features for
children in this age group exist [7-9,17,18] but are not
feasible in resource-poor settings, because they need
expensive materials and are very time consuming.
Therefore a feasible and age-adapted examination tool
was established for this study. In comparison to the tool
developed earlier by Haataja [15], with this new exami-
nation tool the investigation includes neuropsychiatric
features. The detection of neuropsychiatric features was
a main focus because of the known neuropsychiatric
adverse effects of mefloquine in adults [13,19,20]. It is
important to validate these examination tools further to
provide in the future a more valid instrument of neu-
ropsychiatric examination among children, especially of
a young age.
The absence of a double testing excludes the possibi-
lity to measure an interrater reliability. The neurological
and neuropsychiatric safety of the artesunate-mefloquine
combination therapy in young children was the endpoint
of the study. Therefore a standardized examination and
questionnaire by the investigator were assumed to be
sufficient. Precise acoumetry could not be performed,
and therefore no new results to the present knowledge
on hearing impairment related to artemisinin [21-23]
could be added.
The initial assessment of the neurological status of
young children in an acute malaria attack is very diffi-
cult. Children are often not cooperative during the acute
phase of malaria and P. falciparum infection is likely to
negatively influence CNS function [24]. This was
reflected in the observation that one item of the neuro-
logical assessment (forgetfulness) at baseline was not
completed by 66.7% of the children in the applicable age
group. Three other neurological investigation items
(dysdiadochokinesis, disturbed vision, acoustic acuity)
could not be completed among 35-45% of the children
in the applicable age group. When a baseline assessment
was not possible, the follow-up assessments could not
be compared to baseline and therefore an adverse event
could not be properly assessed because it was not clear
whether the disorder was already present at baseline.
However, the results of the study are comparable to the
study in Asian children [2]. Cooperation in a few chil-
dren in this investigation remained difficult and some-
times was even impossible after the acute malaria
Table 2 Neuropsychiatric and neurological disorder
examination at baseline
Symptom Yes No ND
N % N % N %
Dizziness 93 43.7 120 56.3 . .
Headache 85 39.9 114 53.5 14 6.6
Vertigo 14 6.6 191 89.7 8 3.8
Convulsions . . 213 100.0 . .
Paraesthesia 1 1.2 77 93.9 4 4.9
Dysaethesia . . 78 95.1 4 4.9
Sleeplessness (insomnia) 85 39.9 128 60.1 . .
Nightmares 2 6.5 28 90.3 1 3.2
Hyperactivity 18 8.5 195 91.5 . .
Anxiety 26 12.2 187 87.8 . .
Panic Attack 30 14.1 183 85.9 . .
Unexplained sadness 23 10.8 190 89.2 . .
Mood changes 25 11.7 188 88.3 . .
Confusion 4 1.9 208 97.7 1 0.5
Aggressive behavior 19 8.9 194 91.1 . .
Tension 12 5.6 201 94.4 . .
Visual hallucinations 3 3.7 77 93.9 2 2.4
Acoustic hallucinations . . 78 95.1 4 4.9
Hearing loss . . 211 99.1 2 0.9
Dysarthria 3 1.4 205 96.2 5 2.3
Word finding disturbance (1) . . 200 93.9 13 6.1
Eating behavior 154 72.3 59 27.7 . .
Swallowing disturbance . . 213 100.0 . .
Tremor . . 205 96.2 8 3.8
Dystonia, ataxia 3 1.4 209 98.1 1 0.5
Hypereflexia . . 213 100.0 . .
Hyporeflexia 8 3.8 205 96.2 . .
Clonus . . 213 100.0 . .
Dysdiadochokinesis 1 0.5 137 64.3 75 35.2
Disturbed vision . . 128 60.1 85 39.9
Nystagmus . . 192 90.1 21 9.9
Double vision 1 1.2 62 75.6 19 23.2
Acoustic acuity 1 0.5 100 53.8 85 45.7
Forgetfullness 1 0.5 70 32.9 142 66.7
Word finding disturbance (2) 1 1.2 68 82.9 13 15.9
Nightmares were only assessed in children 5 years in age or older.
Paraesthesia, dysaethesia, visual and acoustic hallucinations, double vision and
word finding disturbance (2) were only assessed in children 3.5 years in age
or older.
Acoustic acuity was only assessed in children 1.5 years in age and or older.
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symptoms had disappeared. Another limitation of this
study is that there is no control group of healthy chil-
dren. However, the intra subject design compensates
this limitation.
Concomitant medication can influence neurological and
neuropsychiatric examination. 73.5% of the children
received analgesic medication; more than 50% took anti-
anaemic medication. These results show that this study is
a field study, where the safety of the mefloquine-artesu-
nate therapy was evaluated in every day use. Less than 4%
showed drug-related neurological and neuropsychiatric
adverse events despite the fact that three-quarters of all
children had taken concomitant medication, resulting in
potential additional drug interactions and adverse events.
Conclusion
The first assessment of neurological and neuropsychia-
tric safety of artesunate-mefloquine combination therapy
in 213 African children with acute P. falciparum malaria
and artesunate-mefloquine combination therapy over a
period of 63 days showed no serious drug-related neuro-
logical or neuropsychiatric events. Less than 4% showed
mild to moderate transient drug-related neurological or
neuropsychiatric disorders, and most of them sleeping
disorders. This study does not entirely exclude subtle or
rare CNS effects of artesunate or mefloquine treatment,
but underlines the neurological and neuropsychiatric
safety of the paediatric fixed-dose combination of arte-
sunate and mefloquine in young African children treated
with artesunate-mefloquine for acute falciparum malaria.
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